Delmar Caldwell, MD
Ophthalmology · New Orleans, LANPI 1053403881
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $235 of the $265 with a category attached, or 88.7%. 9 manufacturers reported payments, led by Alcon at 26.6% of the total. Reporting peaked in 2019 at $107 and has fallen 78.6% since, to $23 in 2024. That places this record below the midpoint for ophthalmology clinicians in LA, where the typical reported total is $1,997.
Across 12 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$71
- AbbVie$35
- Merz North America, Inc.$30
- Bausch & Lomb Americas Inc.$24
- Biotissue Holdings Inc.$24
- Carl Zeiss Meditec USA, Inc.$23
- plus $58 from 3 others
Across 90 payments — averaging $3126.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$268K
- Regeneron$13K
What the payments were for
- Food & beverage$23589%
- Gifts$3011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 3 | $71 |
| AbbVie | 2 | $35 |
| Merz North America, Inc. | 1 | $30 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $24 |
| Carl Zeiss Meditec USA, Inc. | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $17 |
How this compares
$265 in reported general payments places this provider in the 15th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 42 | $1,887 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $696 |
| Dorzolamide Hcl | 31 | $598 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $439 |
| Latanoprost | 56 | $424 |
| Brimonidine Tartrate | 33 | $365 |
| Timolol Maleate | 31 | $156 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New Orleans
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Peter KastlNew Orleans$32K
- Benjamin LeeNew Orleans$7K
- Glen CangelosiNew Orleans$6K
- Matthew BoltonNew Orleans$5K
- Barry LeaderNew Orleans$5K
- Blake WilliamsonBaton Rouge$443K
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.